drugset / Trial / NCT02538432

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

NCT02538432

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.

Timeline

Start
2017-06
Primary completion
2019-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject grapiprant Small molecule 250 mg Oral